FDA Revises Guidance for Sponsors of Rare Disease Drug Trials

Drug Industry Daily
A A
As the partial government shutdown grinds on, the FDA resumed issuing guidance on Wednesday with a revised draft guidance to help sponsors of rare disease treatments conduct more effective clinical trials.

To View This Article:

Login

Subscribe To Drug Industry Daily